ReviewMolecular and cellular biochemistry2026
The pivotal role of mitochondria in the pathogenesis and treatment of liver failure: a comprehensive review.
Review in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) are characterized by high mortality rates. A growing body of evidence highlights mitochondrial dysregulation as a central pathogenic driver in these diseases. We provide a detailed examination of mitochondrial structure and core physiological functions in hepatic homeostasis, including mitochondrial DNA (mtDNA) replication, adenosine triphosphate (ATP) generation, reactive oxygen species (ROS) homeostasis, cell apoptosis, calcium homeostasis, mitophagy and mitochondrial biogenesis. We further elaborate on the key mechanisms underlying mitochondrial dysfunction in liver failure, including mitochondrial structural dysfunction, mtDNA damage, energy metabolism disruption, oxidative stress imbalance, inflammatory response dysregulation, cell apoptosis dysregulation, calcium homeostasis imbalance and autophagy dysregulation. These pathological processes are triggered or exacerbated by multiple factors, including genetic defects, drugs/toxins, and viral/bacterial infections. Recognizing the pivotal role of mitochondria, we summarize promising therapeutic interventions that have emerged, encompassing mitochondrial protection, mitochondrial restoration and mitochondrial replacement. Finally, we outline critical unresolved gaps in the field, such as the determinants of hepatocyte mitochondrial selective vulnerability, validated mitochondrial-specific biomarkers, and synergistic interactions between causative factors. Collectively, this review summarizes the multifaceted role of mitochondrial dysfunction in ALF/ACLF and highlights targeted strategies to interrupt the pathogenic cascade, offering potential avenues to improve patient outcomes.
Indexed as
Identifiers
41689714What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.